International Validation of a Nomogram to Predict Recurrence after Resection of Grade 1 and 2 Nonfunctioning Pancreatic Neuroendocrine Tumors
Charlotte M. Heidsma(Amsterdam University Medical Centers), E.J.M. Nieveen van Dijkum(Amsterdam University Medical Centers), Jaswinder S. Samra(The University of Sydney), Marc G. Besselink(Amsterdam Neuroscience), Susan van Dieren(Amphia Ziekenhuis), Simon Schimmack(Heidelberg University), Anthony J. Gill(The University of Sydney), Anubhav Mittal(The University of Sydney), Vikram Deshpande(Beth Israel Deaconess Medical Center), Frederik J.H. Hoogwater(University Medical Center Groningen), Stijn van Roessel(Amsterdam University Medical Centers), Florian Primavesi(Innsbruck Medical University), Josefine Kjaer(Uppsala University), Oliver Strobel(Medical University of Vienna), Olov Norlén(Uppsala University), Julie Périnel(Hôpital Edouard Herriot), Stefan Stättner(Innsbruck Medical University), Anton F. Engelsman(The University of Sydney), Mustapha Adham, Markus W. Buechler(Heidelberg University), Casper H.J. van Eijck(Erasmus MC)
Cited by 13
Related Papers
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
|Journal of Clinical Oncology|2020|1.1k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914